Integrin alpha-IIb
OrganismNot specified
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Other combination Heteromer Protein × 4 其他Polymer 5 PDB declaration: tetrameric（4） Consistent with protein copy count | Chain A； UniProt 1–1039 Chain C； UniProt 1–1039 | Not recorded | Integrin beta-3 × 2 （P05106） beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose × 2 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose × 2 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-beta-D-mannopyranose × 1 CA CALCIUM ION × 12 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 8 MG MAGNESIUM ION × 2 | ELECTRON MICROSCOPY cryo-EM buffer：pH 7.4 cryo-EM vitrification conditions：Cryogen ETHANE | Resolution 3.00 Å |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 9E8C | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1DPK SOLUTION STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE INTEGRIN ALPHA-IIB SUBUNIT Deposited 1999-12-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1020–1039（20 aa）
Fragment：CYTOPLASMIC DOMAIN
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 5；298 K；Ionic strength (raw mmCIF value) 50 mM NACL；Pressure 1
NMR sample composition
3MM PEPTIDE
|
Resolution not provided |
| 1DPQ SOLUTION STRUCTURE OF THE CONSTITUTIVELY ACTIVE MUTANT OF THE INTEGRIN ALPHA IIB CYTOPLASMIC DOMAIN. Deposited 1999-12-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1020–1039（20 aa）
Fragment：CYTOPLASMIC DOMAIN
|
Mutation：P1029A/P1030A | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 5；298 K；Ionic strength (raw mmCIF value) 50 mM NACL；Pressure 1
NMR sample composition
3 MM PEPTIDE
|
Resolution not provided |
| 1KUP Solution Structure of the Membrane Proximal Regions of alpha-IIb and beta-3 Integrins Deposited 2002-01-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1018–1028（11 aa）
Fragment：Membrane proximal region
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 5.2；298 K；Pressure ambient
NMR sample composition
2 mM aIIb/b3 peptides; pH 5.2 (unbuffered), 90% H2O 10% D2O | 90% H2O/10% D2O
NMR sample composition
2 mM aIIb/b3 peptides; pH 5.2 (unbuffered), 100% D2O | 100% D2O
|
Resolution not provided |
| 1KUZ Solution Structure of the Membrane Proximal Regions of alpha-IIb and beta-3 Integrins Deposited 2002-01-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1018–1028（11 aa）
Fragment：Membrane proximal region
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 5.2；298 K；Pressure ambient
NMR sample composition
2 mM aIIb/b3 peptides; pH 5.2 (unbuffered), 90% H2O 10% D2O | 90% H2O/10% D2O
NMR sample composition
2 mM aIIb/b3 peptides; pH 5.2 (unbuffered), 100% D2O | 100% D2O
|
Resolution not provided |
| 1M8O Platelet integrin alfaIIb-beta3 cytoplasmic domain Deposited 2002-07-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1020–1039（20 aa）
Fragment：cytoplasmic domain
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.3
NMR sample composition
1mM 15N/13C MBP-beta3,
1.3 mM unlabeled alfaIIb, | 20 mM phosphate buffer pH6.3
5mM Ca
NMR sample composition
1mM 15N/13C MBP-alfaiib,
1.3 mM unlabeled beta3, | 20 mM phosphate buffer pH6.3
5mM Ca
NMR sample composition
1mM unlabeled alfaIIB,
0.1 mM unlabeled MBP-beta3,
0.2 mM unlabeled talin head domain | 20 mM phosphate buffer pH6.3
5mM Ca
|
Resolution not provided |
| 1S4W NMR structure of the cytoplasmic domain of integrin AIIb in DPC micelles Deposited 2004-01-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1020–1039（20 aa）
Fragment：cytoplasmic domain (residues 1020-1039)
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.3；313 K
NMR sample composition
300 mM dDPC, 95/5% H2O/D2O | 95/5% H2O/D2O
|
Resolution not provided |
| 1TYE Structural basis for allostery in integrins and binding of ligand-mimetic therapeutics to the platelet receptor for fibrinogen Deposited 2004-07-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
32–483（452 aa）
Fragment：residues 1-452
|
Not recorded | CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 CAC CACODYLATE ION × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；10% PEG 8000, 0.4 M magnesium acetate, 0.1 M sodium cacodylate, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.90 Å R-free 0.254 |
| 1TYE Structural basis for allostery in integrins and binding of ligand-mimetic therapeutics to the platelet receptor for fibrinogen Deposited 2004-07-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
32–483（452 aa）
Fragment：residues 1-452
|
Not recorded | CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 CAC CACODYLATE ION × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；10% PEG 8000, 0.4 M magnesium acetate, 0.1 M sodium cacodylate, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.90 Å R-free 0.254 |
| 1TYE Structural basis for allostery in integrins and binding of ligand-mimetic therapeutics to the platelet receptor for fibrinogen Deposited 2004-07-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
32–483（452 aa）
Fragment：residues 1-452
|
Not recorded | CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 CAC CACODYLATE ION × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；10% PEG 8000, 0.4 M magnesium acetate, 0.1 M sodium cacodylate, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.90 Å R-free 0.254 |
| 2K1A Bicelle-embedded integrin alpha(IIB) transmembrane segment Deposited 2008-02-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
989–1029（41 aa）
Fragment：Transmembrane region
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.4；308.2 K；Ionic strength (raw mmCIF value) 0.025；Pressure ambient
NMR sample composition
0.6 mM [U-100% 13C; U-100% 15N; 80% 2H] protein, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided |
| 2K9J Integrin alphaIIb-beta3 transmembrane complex Deposited 2008-10-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
989–1029（41 aa）
Fragment：Transmembrane domain
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.4；301.2 K；Ionic strength (raw mmCIF value) 0.025；Pressure ambient
NMR sample composition
1.2 mM [U-100% 13C; U-100% 15N; 80% 2H] Integrin alpha-IIb light chain, 1.2 mM [U-100% 13C; U-100% 15N; 80% 2H] Integrin beta-3, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided |
| 2KNC Platelet integrin ALFAIIB-BETA3 transmembrane-cytoplasmic heterocomplex Deposited 2009-08-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
991–1039（49 aa）
Fragment：transmembrane and cytoplasmic domains, residues 991-1039
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
25 K；Ionic strength (raw mmCIF value) 0；Pressure AMBIENT
NMR sample composition
0.2 MM [U-100% 13C U-100% 15N] AIIBTMCD, 0.6 MM B3TMCD, 50% CD3CN/50% H2O, 0.1% TFA | 50% CD3CN/50% H2O
NMR sample composition
0.2 MM [U-100% 13C U-100% 15N] B3TMCD, 0.6 MM AIIBTMCD, 50% CD3CN/50% H2O, 0.1% TFA | 50% CD3CN/50% H2O
NMR sample composition
0.4 MM [U-100% 2H U-100% 15N] B3TMCD, 1.2 MM AIIBTMCD, 50% CD3CN/50% H2O, 0.1% TFA | 50% CD3CN/50% H2O
NMR sample composition
0.4 MM [U-100% 2H U-100% 15N] AIIBTMCD, 1.2 MM B3TMCD, 50% CD3CN/50% H2O, 0.1% TFA | 50% CD3CN/50% H2O
|
Resolution not provided |
| 2MTP The structure of Filamin repeat 21 bound to integrin Deposited 2014-08-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
1019–1039（21 aa）
Fragment：UNP residues 1019-1039
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.4；298 K；Ionic strength (raw mmCIF value) 25；Pressure ambient
NMR sample composition
1 mM [U-100% 13C; U-100% 15N; U-80% 2H] protein, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2N9Y Structure of the Integrin alphaIIb-beta3(A711P) Transmembrane Complex Deposited 2015-12-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
989–1029（41 aa）
Fragment：Helical transmembrane residues 989-1029
|
Mutation：A963C | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.4；313 K；Ionic strength (raw mmCIF value) 0.05；Pressure ambient
NMR sample composition
0.8 mM [U-15N; U-2H] alphaIIb, 0.8 mM beta3, 93% H2O/7% D2O | 93% H2O/7% D2O
NMR sample composition
0.8 mM alphaIIb, 0.8 mM [U-15N; U-2H] beta3, 93% H2O/7% D2O | 93% H2O/7% D2O
NMR sample composition
0.8 mM [U-99% 13C; U-99% 15N; 80% 2H] alphaIIb, 0.8 mM [U-99% 13C; U-99% 15N; 80% 2H] beta3, 93% H2O/7% D2O | 93% H2O/7% D2O
|
Resolution not provided |
| 2VC2 Re-refinement of Integrin AlphaIIbBeta3 Headpiece Bound to Antagonist L-739758 Deposited 2007-09-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–483（452 aa）
Fragment：HEADPIECE, RESIDUES 32-483
|
Not recorded | MG MAGNESIUM ION × 2 GOL GLYCEROL × 2 CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 180 2-(S)-[N-(3-PYRIDYLSULFONYL)AMINO]-3-[[2-CARBONYL-5-[2-(PIPERIDIN-4-YL)ETHYL]-THIENO[2,3-B]THIOPHENEYL]AMINO]-PROPIONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；10-12% PEG 3350, 0.7 M MAGNESIUM ACETATE, 0.1 M IMIDAZOLE, PH 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 3.10 Å R-free 0.217 |
| 2VDK Re-refinement of Integrin AlphaIIbBeta3 Headpiece Deposited 2007-10-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–483（452 aa）
Fragment：HEADPIECE, RESIDUES 32-483
|
Not recorded | GOL GLYCEROL × 2 CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 CAC CACODYLATE ION × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；11% PEG 3350, 0.7 M MAGNESIUM ACETATE, 0.1 M SODIUM CACODYLATE, PH 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 2.80 Å R-free 0.205 |
| 2VDL Re-refinement of Integrin AlphaIIbBeta3 Headpiece Deposited 2007-10-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–483（452 aa）
Fragment：HEADPIECE, RESIDUES 32-483
|
Not recorded | GOL GLYCEROL × 2 CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 CAC CACODYLATE ION × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；11% PEG 3350, 0.7 M MAGNESIUM ACETATE, 0.1 M SODIUM CACODYLATE, PH 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 2.75 Å R-free 0.191 |
| 2VDM Re-refinement of Integrin AlphaIIbBeta3 Headpiece Bound to Antagonist Tirofiban Deposited 2007-10-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–483（452 aa）
Fragment：HEADPIECE, RESIDUES 32-483
|
Not recorded | GOL GLYCEROL × 2 CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 AGG TIROFIBAN × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；10-12% PEG3350, 0.7 M MAGNESIUM ACETATE, 0.1 M IMIDAZOLE, PH 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 2.90 Å R-free 0.206 |
| 2VDN Re-refinement of Integrin AlphaIIbBeta3 Headpiece Bound to Antagonist Eptifibatide Deposited 2007-10-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–483（452 aa）
Fragment：HEADPIECE, RESIDUES 32-483
|
Not recorded | GOL GLYCEROL × 2 CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；11% PEG 3350, 0.7 M MAGNESIUM ACETATE, 0.1 M IMIDAZOLE, PH 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 2.90 Å R-free 0.213 |
| 2VDO Integrin AlphaIIbBeta3 Headpiece Bound to Fibrinogen Gamma chain peptide, HHLGGAKQAGDV Deposited 2007-10-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–483（452 aa）
Fragment：HEADPIECE, RESIDUES 32-483
|
Not recorded | GOL GLYCEROL × 2 CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；11% PEG 3350, 0.7 M MAGNESIUM ACETATE, 0.1 M SODIUM CACODYLATE, PH 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 2.51 Å R-free 0.190 |
| 2VDP Integrin AlphaIIbBeta3 Headpiece Bound to Fibrinogen Gamma chain peptide,LGGAKQAGDV Deposited 2007-10-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–483（452 aa）
Fragment：HEADPIECE, RESIDUES 32-483
|
Not recorded | GOL GLYCEROL × 2 CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；11% PEG 3350, 0.7 M MAGNESIUM ACETATE, 0.1 M SODIUM CACODYLATE, PH 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 2.80 Å R-free 0.204 |
| 2VDQ Integrin AlphaIIbBeta3 Headpiece Bound to a Chimeric Fibrinogen Gamma chain peptide, HHLGGAKQRGDV Deposited 2007-10-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–483（452 aa）
Fragment：HEADPIECE, RESIDUES 32-483
|
Not recorded | GOL GLYCEROL × 2 CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；11% PEG 3350, 0.7 M MAGNESIUM ACETATE, 0.1 M SODIUM CACODYLATE, PH 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 2.59 Å R-free 0.190 |
| 2VDR Integrin AlphaIIbBeta3 Headpiece Bound to a chimeric Fibrinogen Gamma chain peptide, LGGAKQRGDV Deposited 2007-10-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–483（452 aa）
Fragment：HEADPIECE, RESIDUES 32-483
|
Not recorded | GOL GLYCEROL × 2 CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；11% PEG 3350, 0.7 M MAGNESIUM ACETATE, 0.1 M SODIUM CACODYLATE, PH 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 2.40 Å R-free 0.193 |
| 3NID The Closed Headpiece of Integrin alphaIIB beta3 and its Complex with an alpahIIB beta3 -Specific Antagonist That Does Not Induce Opening Deposited 2010-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：Integrin alpha-IIb, residues 32-488
|
Not recorded | CA CALCIUM ION × 6 GOL GLYCEROL × 7 SO4 SULFATE ION × 4 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.30 Å R-free 0.215 |
| 3NID The Closed Headpiece of Integrin alphaIIB beta3 and its Complex with an alpahIIB beta3 -Specific Antagonist That Does Not Induce Opening Deposited 2010-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：Integrin alpha-IIb, residues 32-488
|
Not recorded | CA CALCIUM ION × 6 GOL GLYCEROL × 2 SO4 SULFATE ION × 6 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.30 Å R-free 0.215 |
| 3NIF The Closed Headpiece of Integrin IIb 3 and its Complex with an IIb 3 -Specific Antagonist That Does Not Induce Opening Deposited 2010-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：Integrin alpha-IIb, residues 32-488
|
Not recorded | CA CALCIUM ION × 6 NIF 2-ethyl-7-piperazin-1-yl-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one × 1 GOL GLYCEROL × 7 SO4 SULFATE ION × 9 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.40 Å R-free 0.216 |
| 3NIF The Closed Headpiece of Integrin IIb 3 and its Complex with an IIb 3 -Specific Antagonist That Does Not Induce Opening Deposited 2010-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：Integrin alpha-IIb, residues 32-488
|
Not recorded | CA CALCIUM ION × 6 NIF 2-ethyl-7-piperazin-1-yl-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 9 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.40 Å R-free 0.216 |
| 3NIG The Closed Headpiece of Integrin IIb 3 and its Complex with an IIb 3 -Specific Antagonist That Does Not Induce Opening Deposited 2010-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：Integrin alpha-IIb, residues 32-488
|
Not recorded | CA CALCIUM ION × 6 GOL GLYCEROL × 2 SO4 SULFATE ION × 3 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.25 Å R-free 0.212 |
| 3NIG The Closed Headpiece of Integrin IIb 3 and its Complex with an IIb 3 -Specific Antagonist That Does Not Induce Opening Deposited 2010-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：Integrin alpha-IIb, residues 32-488
|
Not recorded | CA CALCIUM ION × 6 GOL GLYCEROL × 1 SO4 SULFATE ION × 3 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.25 Å R-free 0.212 |
| 3T3M A Novel High Affinity Integrin alphaIIbbeta3 Receptor Antagonist That Unexpectedly Displaces Mg2+ from the beta3 MIDAS Deposited 2011-07-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP residues 32-488
|
Not recorded | CA CALCIUM ION × 6 RC2 N-{3-[5-oxo-7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]phenyl}glycinamide × 1 SO4 SULFATE ION × 4 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.60 Å R-free 0.222 |
| 3T3M A Novel High Affinity Integrin alphaIIbbeta3 Receptor Antagonist That Unexpectedly Displaces Mg2+ from the beta3 MIDAS Deposited 2011-07-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP residues 32-488
|
Not recorded | CA CALCIUM ION × 6 RC2 N-{3-[5-oxo-7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]phenyl}glycinamide × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.60 Å R-free 0.222 |
| 3T3P A Novel High Affinity Integrin alphaIIbbeta3 Receptor Antagonist That Unexpectedly Displaces Mg2+ from the beta3 MIDAS Deposited 2011-07-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP residues 32-488
|
Not recorded | SO4 SULFATE ION × 4 GOL GLYCEROL × 1 CA CALCIUM ION × 6 CL CHLORIDE ION × 1 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.20 Å R-free 0.220 |
| 3T3P A Novel High Affinity Integrin alphaIIbbeta3 Receptor Antagonist That Unexpectedly Displaces Mg2+ from the beta3 MIDAS Deposited 2011-07-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP residues 32-488
|
Not recorded | SO4 SULFATE ION × 3 CA CALCIUM ION × 6 CL CHLORIDE ION × 3 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.20 Å R-free 0.220 |
| 3ZDX Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：INTEGRIN HEADPIECE, RESIDUES 32-488
|
Not recorded | GOL GLYCEROL × 4 SO4 SULFATE ION × 3 CA CALCIUM ION × 4 CL CHLORIDE ION × 1 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL, PH 8.9
|
Resolution 2.45 Å R-free 0.197 |
| 3ZDX Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：INTEGRIN HEADPIECE, RESIDUES 32-488
|
Not recorded | GOL GLYCEROL × 2 SO4 SULFATE ION × 7 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL, PH 8.9
|
Resolution 2.45 Å R-free 0.197 |
| 3ZDY Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–488（457 aa）
Fragment：RESIDUES 32-488
|
Not recorded | SO4 SULFATE ION × 14 CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL, PH 8.9
|
Resolution 2.45 Å R-free 0.216 |
| 3ZDY Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
32–488（457 aa）
Fragment：RESIDUES 32-488
|
Not recorded | SO4 SULFATE ION × 6 CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL, PH 8.9
|
Resolution 2.45 Å R-free 0.216 |
| 3ZDZ Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–488（457 aa）
Fragment：RESIDUES 32-488
|
Not recorded | SO4 SULFATE ION × 2 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL, PH 8.9
|
Resolution 2.75 Å R-free 0.221 |
| 3ZDZ Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
32–488（457 aa）
Fragment：RESIDUES 32-488
|
Not recorded | SO4 SULFATE ION × 1 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL, PH 8.9
|
Resolution 2.75 Å R-free 0.221 |
| 3ZE0 Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–488（457 aa）
Fragment：RESIDUES 32-488
|
Not recorded | SO4 SULFATE ION × 4 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL, PH 8.9
|
Resolution 2.95 Å R-free 0.243 |
| 3ZE0 Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
32–488（457 aa）
Fragment：RESIDUES 32-488
|
Not recorded | SO4 SULFATE ION × 1 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL, PH 8.9
|
Resolution 2.95 Å R-free 0.243 |
| 3ZE1 Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–488（457 aa）
Fragment：RESIDUES 32-488
|
Not recorded | SO4 SULFATE ION × 3 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL PH 8.9
|
Resolution 3.00 Å R-free 0.233 |
| 3ZE1 Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
32–488（457 aa）
Fragment：RESIDUES 32-488
|
Not recorded | CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL PH 8.9
|
Resolution 3.00 Å R-free 0.233 |
| 3ZE2 Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–488（457 aa）
Fragment：RESIDUE 32-488
|
Not recorded | GOL GLYCEROL × 5 SO4 SULFATE ION × 2 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL, PH 8.9
|
Resolution 2.35 Å R-free 0.204 |
| 3ZE2 Integrin alphaIIB beta3 headpiece and RGD peptide complex Deposited 2012-12-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
32–488（457 aa）
Fragment：RESIDUE 32-488
|
Not recorded | GOL GLYCEROL × 5 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9；11% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M TRIS-HCL, PH 8.9
|
Resolution 2.35 Å R-free 0.204 |
| 4CAK Three-dimensional reconstruction of intact human integrin alphaIIbbeta3 in a phospholipid bilayer nanodisc Deposited 2013-10-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
32–990（959 aa）
Fragment：ECTODOMAIN, UNP RESIDUES 32-990
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
150 MM NACL, 10 MM HEPES, PH 7.4, 1 MM CACL2 AND 1 MM MGCL2；pH 7.4；150 MM NACL, 10 MM HEPES, PH 7.4, 1 MM CACL2 AND 1 MM MGCL2
cryo-EM vitrification conditions
VITRIFICATION 1 -- CRYOGEN- NONE, INSTRUMENT- NONE,
|
Resolution 20.50 Å |
| 4Z7N Integrin alphaIIbbeta3 in complex with AGDV peptide Deposited 2015-04-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–486（455 aa）
Fragment：UNP residues 32-486
|
Not recorded | CA CALCIUM ION × 4 SO4 SULFATE ION × 5 GOL GLYCEROL × 1 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.60 Å R-free 0.253 |
| 4Z7N Integrin alphaIIbbeta3 in complex with AGDV peptide Deposited 2015-04-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
32–486（455 aa）
Fragment：UNP residues 32-486
|
Not recorded | CA CALCIUM ION × 4 SO4 SULFATE ION × 3 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.60 Å R-free 0.253 |
| 4Z7O Integrin alphaIIbbeta3 in complex with AGDV peptide Deposited 2015-04-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–486（455 aa）
Fragment：UNP residues 32-486
|
Not recorded | SO4 SULFATE ION × 2 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.85 Å R-free 0.257 |
| 4Z7O Integrin alphaIIbbeta3 in complex with AGDV peptide Deposited 2015-04-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
32–486（455 aa）
Fragment：UNP residues 32-486
|
Not recorded | SO4 SULFATE ION × 1 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.85 Å R-free 0.257 |
| 4Z7Q Integrin alphaIIbbeta3 in complex with AGDV-NH2 peptide Deposited 2015-04-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: pentameric |
Chain A
32–485（454 aa）
Fragment：UNP residues 32-486
|
Not recorded | CA CALCIUM ION × 4 SO4 SULFATE ION × 4 GOL GLYCEROL × 1 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.70 Å R-free 0.236 |
| 4Z7Q Integrin alphaIIbbeta3 in complex with AGDV-NH2 peptide Deposited 2015-04-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: pentameric |
Chain C
32–485（454 aa）
Fragment：UNP residues 32-486
|
Not recorded | CA CALCIUM ION × 4 SO4 SULFATE ION × 3 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MAN alpha-D-mannopyranose × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.70 Å R-free 0.236 |
| 5HDB Integrin alphaIIbbeta3 in complex with Ro-435054 Deposited 2016-01-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 3 GOL GLYCEROL × 1 CA CALCIUM ION × 5 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 5YB N-(4-carbamimidoylbenzoyl)-beta-alanyl-L-alpha-aspartyl-L-phenylalanine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.70 Å R-free 0.237 |
| 5HDB Integrin alphaIIbbeta3 in complex with Ro-435054 Deposited 2016-01-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 2 CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 5YB N-(4-carbamimidoylbenzoyl)-beta-alanyl-L-alpha-aspartyl-L-phenylalanine × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.70 Å R-free 0.237 |
| 6V4P Structure of the integrin AlphaIIbBeta3-Abciximab complex Deposited 2019-11-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–963（963 aa）
|
Not recorded | CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 2.80 Å |
| 7KN0 Structure of the integrin aIIb(W968V)b3 transmembrane complex Deposited 2020-11-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
989–1029（41 aa）
|
Mutation：A963G, W968V | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.4；313.2 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR sample composition
0.8 mM [U-100% 13C; U-100% 15N; U-80% 2H] transmembrane complex, 93% H2O/7% D2O | 93% H2O/7% D2O
|
Resolution not provided |
| 7L8P Integrin alphaIIbbeta3 in complex with sibrafiban Deposited 2020-12-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 4 GOL GLYCEROL × 1 CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 XQS sibrafiban (active form) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.35 Å R-free 0.245 |
| 7L8P Integrin alphaIIbbeta3 in complex with sibrafiban Deposited 2020-12-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 3 CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 XQS sibrafiban (active form) × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.35 Å R-free 0.245 |
| 7LA4 Integrin AlphaIIbBeta3-PT25-2 Complex Deposited 2021-01-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–1039（1039 aa）
|
Not recorded | CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 7SC4 filamin complex-1 Deposited 2021-09-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1019–1039（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289.15 K；2 M Ammonium Sulfate, 5% 2-propanol
|
Resolution 1.85 Å R-free 0.261 |
| 7SC4 filamin complex-1 Deposited 2021-09-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1019–1039（21 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289.15 K；2 M Ammonium Sulfate, 5% 2-propanol
|
Resolution 1.85 Å R-free 0.261 |
| 7SFT Filamin complex-2 Deposited 2021-10-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1019–1039（21 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.4；298 K；Ionic strength (raw mmCIF value) 61；Pressure 1
NMR sample composition
1 mM [U-100% 13C; U-100% 15N] filamin Ig21, 2 mM Integrin alpha-IIb light chain, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-15N; U-2H] filamin Ig21, 2 mM Integrin alpha-IIb light chain, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
2 mM Integrin alpha-IIb light chain, 0.05 mM GST-filamin-Ig21, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 7TCT Integrin alpha IIB beta3 complex with UR2922 Deposited 2021-12-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | CA CALCIUM ION × 6 SO4 SULFATE ION × 5 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 I1F {5-[N-(4-carbamimidoylbenzoyl)-4-nitro-L-phenylalanyl]-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl}acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.50 Å R-free 0.227 |
| 7TCT Integrin alpha IIB beta3 complex with UR2922 Deposited 2021-12-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | CA CALCIUM ION × 6 SO4 SULFATE ION × 3 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 I1F {5-[N-(4-carbamimidoylbenzoyl)-4-nitro-L-phenylalanyl]-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl}acetic acid × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.50 Å R-free 0.227 |
| 7TD8 Integrin alpha IIB beta3 complex with Tirofiban Deposited 2021-12-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–484（453 aa）
|
Not recorded | CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 SO4 SULFATE ION × 5 MG MAGNESIUM ION × 1 AGG TIROFIBAN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.60 Å R-free 0.210 |
| 7TD8 Integrin alpha IIB beta3 complex with Tirofiban Deposited 2021-12-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–484（453 aa）
|
Not recorded | CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 SO4 SULFATE ION × 3 MG MAGNESIUM ION × 1 AGG TIROFIBAN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.60 Å R-free 0.210 |
| 7THO Integrin alpha IIB beta3 complex with Eptifibatide Deposited 2022-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–485（454 aa）
|
Not recorded | CA CALCIUM ION × 6 SO4 SULFATE ION × 2 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.75 Å R-free 0.222 |
| 7THO Integrin alpha IIB beta3 complex with Eptifibatide Deposited 2022-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
32–485（454 aa）
|
Not recorded | CA CALCIUM ION × 6 SO4 SULFATE ION × 2 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.75 Å R-free 0.222 |
| 7TMZ Integrin alpha IIB beta3 complex with BMS compound 4 Deposited 2022-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 6 CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 I7R (4-{[(5S)-3-{4-[(E)-imino(4-methylpiperazin-1-yl)methyl]phenyl}-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperazin-1-yl)acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.20 Å R-free 0.241 |
| 7TMZ Integrin alpha IIB beta3 complex with BMS compound 4 Deposited 2022-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 4 CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 I7R (4-{[(5S)-3-{4-[(E)-imino(4-methylpiperazin-1-yl)methyl]phenyl}-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperazin-1-yl)acetic acid × 1 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.20 Å R-free 0.241 |
| 7TPD Integrin alpha IIB beta3 complex with EF5154 Deposited 2022-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | CA CALCIUM ION × 6 SO4 SULFATE ION × 3 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 IR7 (4-{[2-oxo-4-(piperidin-4-yl)piperazin-1-yl]acetyl}phenoxy)acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.60 Å R-free 0.194 |
| 7TPD Integrin alpha IIB beta3 complex with EF5154 Deposited 2022-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | CA CALCIUM ION × 6 SO4 SULFATE ION × 2 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 IR7 (4-{[2-oxo-4-(piperidin-4-yl)piperazin-1-yl]acetyl}phenoxy)acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.60 Å R-free 0.194 |
| 7U60 Integrin alpha IIB beta3 complex with cRGDfV Deposited 2022-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
32–486（455 aa）
Fragment：UNP residues 32-486
|
Not recorded | CA CALCIUM ION × 4 GOL GLYCEROL × 8 SO4 SULFATE ION × 6 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.55 Å R-free 0.225 |
| 7U60 Integrin alpha IIB beta3 complex with cRGDfV Deposited 2022-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
32–486（455 aa）
Fragment：UNP residues 32-486
|
Not recorded | CA CALCIUM ION × 4 GOL GLYCEROL × 3 SO4 SULFATE ION × 2 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.55 Å R-free 0.225 |
| 7U9F Integrin alpha IIB beta3 complex with BMS compound 4 in Mn2+ Deposited 2022-03-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 5 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 I7R (4-{[(5S)-3-{4-[(E)-imino(4-methylpiperazin-1-yl)methyl]phenyl}-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperazin-1-yl)acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.70 Å R-free 0.237 |
| 7U9F Integrin alpha IIB beta3 complex with BMS compound 4 in Mn2+ Deposited 2022-03-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 4 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 I7R (4-{[(5S)-3-{4-[(E)-imino(4-methylpiperazin-1-yl)methyl]phenyl}-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperazin-1-yl)acetic acid × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.70 Å R-free 0.237 |
| 7U9V Integrin alpha IIB beta3 complex with BMS4-1 Deposited 2022-03-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 5 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 M6K (4-{[(5S)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperazin-1-yl)acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.25 Å R-free 0.226 |
| 7U9V Integrin alpha IIB beta3 complex with BMS4-1 Deposited 2022-03-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 4 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 M6K (4-{[(5S)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperazin-1-yl)acetic acid × 1 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.25 Å R-free 0.226 |
| 7UBR Integrin alpha IIB beta3 complex with GR144053 Deposited 2022-03-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 7 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MJX {4-[4-(4-carbamimidoylphenyl)piperazin-1-yl]piperidin-1-yl}acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.05 Å R-free 0.223 |
| 7UBR Integrin alpha IIB beta3 complex with GR144053 Deposited 2022-03-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 5 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MJX {4-[4-(4-carbamimidoylphenyl)piperazin-1-yl]piperidin-1-yl}acetic acid × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.05 Å R-free 0.223 |
| 7UCY Integrin alpha IIB beta3 complex with gantofiban Deposited 2022-03-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 5 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MV8 (4-{[(5R)-3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}piperazin-1-yl)acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.35 Å R-free 0.231 |
| 7UCY Integrin alpha IIB beta3 complex with gantofiban Deposited 2022-03-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 4 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MV8 (4-{[(5R)-3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}piperazin-1-yl)acetic acid × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.35 Å R-free 0.231 |
| 7UDG Integrin alpha IIB beta3 complex with lotrafiban Deposited 2022-03-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 5 CA CALCIUM ION × 5 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MWI Lotrafiban × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.80 Å R-free 0.235 |
| 7UDG Integrin alpha IIB beta3 complex with lotrafiban Deposited 2022-03-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 4 CA CALCIUM ION × 5 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MWI Lotrafiban × 1 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.80 Å R-free 0.235 |
| 7UDH Integrin alpha IIB beta3 complex with BMS4-3 Deposited 2022-03-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 5 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MWO (4-{[(5S)-3-(piperidin-4-yl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperazin-1-yl)acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.00 Å R-free 0.214 |
| 7UDH Integrin alpha IIB beta3 complex with BMS4-3 Deposited 2022-03-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 4 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MWO (4-{[(5S)-3-(piperidin-4-yl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperazin-1-yl)acetic acid × 1 MAN alpha-D-mannopyranose × 1 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.00 Å R-free 0.214 |
| 7UE0 Integrin alpha IIB beta3 complex with fradafiban Deposited 2022-03-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 4 GOL GLYCEROL × 1 CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MWX Fradafiban × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.74 Å R-free 0.253 |
| 7UE0 Integrin alpha IIB beta3 complex with fradafiban Deposited 2022-03-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 2 CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MWX Fradafiban × 1 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.74 Å R-free 0.253 |
| 7UFH Integrin alpha IIB beta3 complex with fradafiban (Mn/Ca) Deposited 2022-03-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 5 GOL GLYCEROL × 1 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MWX Fradafiban × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 3.00 Å R-free 0.245 |
| 7UFH Integrin alpha IIB beta3 complex with fradafiban (Mn/Ca) Deposited 2022-03-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 3 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MWX Fradafiban × 1 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 3.00 Å R-free 0.245 |
| 7UH8 Integrin alpha IIB beta3 complex with roxifiban (Mn/Ca) Deposited 2022-03-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 5 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 N9U Roxifiban × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.75 Å R-free 0.248 |
| 7UH8 Integrin alpha IIB beta3 complex with roxifiban (Mn/Ca) Deposited 2022-03-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 4 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 N9U Roxifiban × 1 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.75 Å R-free 0.248 |
| 7UJE Integrin alpha IIB beta3 complex with UR2922 in Mn2+ Deposited 2022-03-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 6 CA CALCIUM ION × 4 GOL GLYCEROL × 1 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 I1F {5-[N-(4-carbamimidoylbenzoyl)-4-nitro-L-phenylalanyl]-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl}acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.50 Å R-free 0.239 |
| 7UJE Integrin alpha IIB beta3 complex with UR2922 in Mn2+ Deposited 2022-03-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–485（454 aa）
|
Not recorded | SO4 SULFATE ION × 3 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 I1F {5-[N-(4-carbamimidoylbenzoyl)-4-nitro-L-phenylalanyl]-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl}acetic acid × 1 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；11-13% PEG 8000, 0.2 M Ammonium Sulfate, 0.1 M Tris-HCl, pH 8.9
|
Resolution 2.50 Å R-free 0.239 |
| 7UJK Integrin alpha IIB beta3 complex with lamifiban Deposited 2022-03-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 4 GOL GLYCEROL × 1 CA CALCIUM ION × 6 CL CHLORIDE ION × 1 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NB9 Lamifiban × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.43 Å R-free 0.247 |
| 7UJK Integrin alpha IIB beta3 complex with lamifiban Deposited 2022-03-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 3 CA CALCIUM ION × 6 CL CHLORIDE ION × 2 MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NB9 Lamifiban × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.43 Å R-free 0.247 |
| 7UK9 Integrin alpha IIB beta3 complex with lamifiban (Mn) Deposited 2022-03-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 5 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NB9 Lamifiban × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.60 Å R-free 0.242 |
| 7UK9 Integrin alpha IIB beta3 complex with lamifiban (Mn) Deposited 2022-03-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 3 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NB9 Lamifiban × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.60 Å R-free 0.242 |
| 7UKO Integrin alpha IIB beta3 complex with sibrafiban (Mn) Deposited 2022-04-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 3 CA CALCIUM ION × 4 GOL GLYCEROL × 2 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 XQS sibrafiban (active form) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.60 Å R-free 0.239 |
| 7UKO Integrin alpha IIB beta3 complex with sibrafiban (Mn) Deposited 2022-04-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 2 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 XQS sibrafiban (active form) × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.60 Å R-free 0.239 |
| 7UKP Integrin alpha IIB beta3 complex with a gantofiban analog Deposited 2022-04-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 3 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NJ9 3-(4-{[(5S)-3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}piperazin-1-yl)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.80 Å R-free 0.241 |
| 7UKP Integrin alpha IIB beta3 complex with a gantofiban analog Deposited 2022-04-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 4 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NJ9 3-(4-{[(5S)-3-(4-carbamimidoylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}piperazin-1-yl)propanoic acid × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.80 Å R-free 0.241 |
| 7UKT Integrin alpha IIB beta3 complex with BMS4.2 Deposited 2022-04-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 5 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NJF (1-{[(5S)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperidin-4-yl)acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.37 Å R-free 0.218 |
| 7UKT Integrin alpha IIB beta3 complex with BMS4.2 Deposited 2022-04-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
32–488（457 aa）
Fragment：UNP Residues 32-488
|
Not recorded | SO4 SULFATE ION × 4 CA CALCIUM ION × 4 MN MANGANESE (II) ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NJF (1-{[(5S)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperidin-4-yl)acetic acid × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.9；277 K；11% PEG 8000, 0.2 M ammonium sulfate, 0.1 M Tris-HCl
|
Resolution 2.37 Å R-free 0.218 |
| 8GCD Full length Integrin AlphaIIbBeta3 in inactive state Deposited 2023-03-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–1039（1039 aa）
|
Not recorded | CA CALCIUM ION × 7 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.97 Å |
| 8GCE The Extracellular Domain of Integrin AlphaIIbBeta3 in Intermediate State Deposited 2023-03-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–1039（1039 aa）
|
Not recorded | CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.12 Å |
| 8T2U Cryo-EM Structures of Full-length Integrin alphaIIbbeta3 in Native Lipids complexed with Eptifibatide Deposited 2023-06-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
32–1039（1008 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；TBS/1mM CaCl2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å |
| 8T2V Cryo-EM Structures of Full-length Integrin alphaIIbbeta3 in Native Lipids Deposited 2023-06-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
32–1039（1008 aa）
|
Not recorded | CA CALCIUM ION × 7 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 CLR CHOLESTEROL × 2 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；TBS/1mM CaCl2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 9AXL Structure of the semi-extended AlphaIIbBeta3 in complex with R21D10 Fab Deposited 2024-03-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–1039（1039 aa）
|
Not recorded | CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 9DAO AlphaIIbbeta3 in fully-extended conformation in complex with R6H8 Fab Deposited 2024-08-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–1039（1008 aa）
|
Not recorded | CA CALCIUM ION × 5 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å |
| 9DAX The structure of AlphaIIbbeta3 in apo state Deposited 2024-08-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
32–1039（1008 aa）
|
Not recorded | CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 9DEQ Cryo-EM structures of full-length integrin alphaIIbbeta3 in native lipids complexed with modified tirofiban Deposited 2024-08-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
32–1039（1008 aa）
|
Not recorded | CA CALCIUM ION × 7 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 MG MAGNESIUM ION × 1 A1A5G N-(1,3-benzoxazole-2-carbonyl)-O-[4-(piperidin-4-yl)butyl]-L-tyrosine × 1 CLR CHOLESTEROL × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；TBS/1mM CaCl2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.10 Å |
| 9DER Cryo-EM Structures of Full-Length Integrin alphaIIbbeta3 in Native Lipids Complexed with Tirofiban Deposited 2024-08-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
32–1039（1008 aa）
|
Not recorded | CA CALCIUM ION × 6 MG MAGNESIUM ION × 1 AGG TIROFIBAN × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；TBS/1mM CaCl2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.90 Å |
| 9E8A Integrin aIIbb3 bent conformation from human platelet membrane crude preparation Deposited 2024-11-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
1–1039（1039 aa）
|
Not recorded | CA CALCIUM ION × 7 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.75 Å |
| 9E8B Integrin aIIbb3 intermediate conformation from human platelet membrane crude preparation Deposited 2024-11-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
32–631（600 aa）
|
Not recorded | CA CALCIUM ION × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 MG MAGNESIUM ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.67 Å |
| 9TD2 Integrin AlphaIIbBeta3 bound to Fab of the anti-HPA-1a antibody 26.4 Deposited 2025-11-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–994（963 aa）
|
Not recorded | No recorded non-water small molecule | ELECTRON MICROSCOPY mmCIF provides none of the parsed conditions | Resolution 2.64 Å |
76 other PDB entries and 116 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | ITA2B_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 1–1039； UniProt 1–1039 Author chain C； PDBConstruct 1–1039； UniProt 1–1039 |
